



(51) International Patent Classification:

C12N 9/22 (2006.01) A61K 9/127 (2006.01)
A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2022/079124

(22) International Filing Date:

02 November 2022 (02.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/275,425 03 November 2021 (03.11.2021) US
63/352,158 14 June 2022 (14.06.2022) US

(71) Applicant: **INTELLIA THERAPEUTICS, INC.**
[US/US]; 40 Erie Street, Cambridge, Massachusetts 02139
(US).

(72) Inventors: **MULEPATI, Sabin**; 40 Erie Street, Cambridge, Massachusetts 02139 (US). **STRETZ, Lindsey Jean**; 40 Erie Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **BAUR, Amelia Feulner et al.**; MCNEILL BAUR PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: POLYNUCLEOTIDES, COMPOSITIONS, AND METHODS FOR GENOME EDITING




Fig. 7

(57) Abstract: Compositions and methods for gene editing are provided. In some embodiments, provided is a polynucleotide encoding an RNA-guided DNA binding agent such as *N. meningitidis* Cas9 that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.